Đăng xuất
Alcohol: At therapeutic doses, no clinically significant interactions have been demonstrated with alcohol (for a blood alcohol level of 0.5 g/L). Nevertheless, precaution is recommended if alcohol is taken concomitantly.
Patients at risk of convulsions: Caution in epileptic patients and patients at risk of convulsions is recommended.
Film-coated tablet: Cetirizine dihydrochloride, 10 mg, film-coated tablets: The product contains lactose. Patients with rare hereditary problems of galactose intolerance, (the Lapp lactase deficiency or glucose-galactose malabsorption) should not take this medicine.
Oral solution: Increased risk of urinary retention: Caution should be taken in patients with predisposing factors of urinary retention (e.g. spinal cord lesion, prostatic hyperplasia) as cetirizine may increase the risk of urinary retention.
Allergy skin tests: Allergy skin tests are inhibited by antihistamines and a wash-out period of 3 days is recommended before performing them.
Food: The extent of absorption of cetirizine is not reduced with food, although the rate of absorption is decreased.
Excipients: Sorbitol: This product contains sorbitol. Patients with rare hereditary problems of fructose intolerance should not take this medicine.
Parabens: This product contains methyl parahydroxybenzoate or propyl parahydroxybenzoate, which may cause allergic reactions (possibly delayed).
Ability to Perform Tasks that Require Judgement, Motor or Cognitive Skills: Objective measurements of driving ability, sleep latency and assembly line performance have not demonstrated any clinically relevant effects at the recommended dose of 10 mg.
Patients intending to drive, engaging in potentially hazardous activities or operating machinery should not exceed the recommended dose and should take their response to the medicinal product into account.
In sensitive patients, concurrent use with alcohol or other CNS depressants may cause additional reductions in alertness and impairment of performance.
Use in Children: Tablet: The use of the film-coated tablet is not recommended in children aged less than 6 years since this formulation does not allow for appropriate dose adaptation. It is recommended to use a pediatric formulation of cetirizine.
